



# Mouse Anti-Mouse CTLA-4 (CD152) Monoclonal antibody, clone 9D9 (CABT-L4442)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

### Product Overview

The 9D9 monoclonal antibody reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the *Ctla4* gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade.

|                           |   |
|---------------------------|---|
| <b>Target</b>             | Mouse CTLA-4 (CD152)                                      |
| <b>Immunogen</b>          | CHO cell line transfected with mouse CD80                 |
| <b>Isotype</b>            | IgG2b   |
| <b>Source/Host</b>        | Mouse   |
| <b>Species Reactivity</b> | Mouse   |
| <b>Clone</b>              | 9D9   |
| <b>Purification</b>       | Protein A purified.<br>Purity>95%. Determined by SDS-PAGE |
| <b>Conjugate</b>          | Functional Grade  |
| <b>Applications</b>       | in vivo CTLA-4 neutralization, WB                         |

|                         |   |
|-------------------------|---|
| <b>Molecular Weight</b> | 150 kDa   |
| <b>Format</b>           | 0.2 $\mu$ M filtered liquid. Purified from tissue culture supernatant in an animal free facility                        |
| <b>Concentration</b>    | Lot specific  |
| <b>Size</b>             | 5 mg  |
| <b>Buffer</b>           | PBS, pH 7.0. Contains no stabilizers or preservatives. [low endotoxin azide-free]                                       |
|                         | Endotoxin level: <2EU/mg (<0.002EU/ $\mu$ g). Determined by LAL gel clotting assay                                      |
|                         | Related dilution buffer: CABT-LB04  |
| <b>Preservative</b>     | None  |
| <b>Storage</b>          | The antibody solution should be stored undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze. |
| <b>Ship</b>             | Wet ice   |

## BACKGROUND

|                     |  |
|---------------------|--|
| <b>Introduction</b> | This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. |
| <b>Keywords</b>     | CTLA-4   |

## GENE INFORMATION

|                        |   |
|------------------------|---|
| <b>Official Symbol</b> | cytotoxic T-lymphocyte-associated protein 4   |
| <b>Synonyms</b>        | CTLA-4  |
| <b>References</b>      | Dai, M., et al. (2015). "Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies." <i>Clin Cancer Res</i> 21(5): 1127-1138. PubMed;Balachandran, V. P., et al. (2011). "Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido." <i>Nat Med</i> 17(9): 1094-1100. PubMed;Curran, M. A., et al. (2011). "Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by |

increasing T-cell infiltration, proliferation, and cytokine production." PLoS One 6(4): e19499. PubMed;

---